Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Testing Whether A Novel MRI Imaging Approach Will Find Aggressive Disease before Surgery, which May Help Physicians Decide the Best Treatment Plan for Patients with Newly Diagnosed Prostate Cancer

This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
Prostate
Phase II
Adults
Not Available
Not Available
Planz, Virginia
National
Vanderbilt University
07-26-2019
Diagnostic
ECOGUROEA8171
NCT03697148

Eligibility

18 Years
MALE
NO
Inclusion Criteria:

Men, age >= 18 years, diagnosed within 120 days prior to registration with prostate cancer for whom definitive surgical treatment is indicated * Note: Patients previously diagnosed with prostate cancer for which surgery is not indicated may be enrolled if they undergo a repeat biopsy (within 120 days prior to registration and for reasons including, but not limited to, discordant biopsy results) that indicates definitive treatment with surgery

Confirmation of payment, insurance pre-authorization, or Medicare for mpMRI



Exclusion Criteria:

Not suitable to undergo MRI or receive gadolinium-based contrast agent (severe, untreatable claustrophobia; MRI-incompatible metallic objects or implanted medical devices; renal failure; weight greater than allowable by scanner per institutional standard practice)

Prior surgical and/or non-surgical treatment for prostate cancer

Prior hip replacement or other major pelvic surgery

Unable to obtain confirmation of payment, insurance pre-authorization, or Medicare for mpMRI

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: